Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Table 2 Baseline characteristics and disease activity

	Placebo (N = 105)	Baricitinib 2 mg (N = 105)	Baricitinib 4 mg (N = 104)
Age, years, mean (SD)	44.9 (12.8)	43.2 (11.0)	45.0 (12.4)
Female, n (%)	99 (94.3)	96 (91.4)	99 (95.2)
Time since onset of SLE symptoms, years, mean (SD)	9.7 (7.7)	11.8 (9.1)	11.5 (10.3)
SLEDAI-2K score, mean (SD)	8.9 (2.9)	8.8 (3.4)	9.0 (3.3)
≥1 A or ≥2 B BILAG scores, n (%)	62 (59.0)	56 (53.3)	69 (66.3)
Physician’s Global Assessment score^a, mean (SD)	1.5 (0.5)	1.5 (0.5)	1.6 (0.5)
Positive anti-dsDNA, n (%)	51 (48.6)	56 (53.3)	53 (51.0)
Anti-dsDNA, IU/mL, median (range)^b	125.8 (33, 999)	139.8 (35, 1167)	128.4 (31, 1864)
Immunoglobulin G, g/L, median (range)^c	13.4 (5.2–53.4)	13.5 (6.3–26.1)	13.0 (6.9–40.6)
Complement C3, g/L, median (range)	1.0 (0.3–1.7)	1.0 (0.4–1.7)	1.1 (0.26–2.0)
Complement C4, g/L, median (range)	0.2 (0.0–0.5)	0.2 (0.0–0.4)	0.2 (0.0–0.9)

Data are presented as mean (standard deviation) unless stated otherwise
^a Scores range from 0 to 3 on a visual analogue scale with higher values indicating more severe disease
^b Reported for patients with anti-dsDNA ≥30 IU/mL at baseline
^c Placebo, n = 101; baricitinib 2 mg, n = 99; baricitinib 4 mg, n = 96)
BILAG British Isles Lupus Assessment Group, C component, dsDNA double-stranded deoxyribonucleic acid, N number of patients, n number of patients in a subgroup, SLE systemic lupus erythematosus, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index-2000

ISSN: 1478-6362